Early Human Development
Volume 86, Issue 4 , Pages 251-254 , April 2010

Increased expression of matrix metalloproteinase-9 and hepatocyte growth factor in the cerebrospinal fluid of infants with posthemorrhagic hydrocephalus

  • Toshio Okamoto

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan
    • Corresponding Author InformationCorresponding author. Department of Pediatrics, Asahikawa Medical College, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan. Tel.: +81 166 68 2481; fax: +81 166 68 2489.
    • ,
  • Satoru Takahashi

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan
    • ,
  • Eiki Nakamura

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan
    • ,
  • Ken Nagaya

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan
    • ,
  • Tokitsugi Hayashi

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan
    • ,
  • Masaru Shirai

      Affiliations

    • Department of Pediatrics, Asahikawa Kosei Hospital, Hokkaido, Japan
    • ,
  • Kenji Fujieda

      Affiliations

    • Department of Pediatrics, Asahikawa Medical College, Hokkaido, Japan

Received 7 December 2009 ,Revised 2 March 2010 ,Accepted 25 March 2010.

References 

  1. Volpe JJ. Intracranial hemorrhage: germinal matrix-intraventricular hemorrhage of the premature infants. In:  Volpe JJ editors. Neurology of the newborn. Philadelphia: Saunders; 2008;p. 517–588
  2. Hill A, Shackelford GD, Volpe JJ. A potential mechanism of pathogenesis for early posthemorrhagic hydrocephalus in the premature newborn. Pediatrics. 1985;73:19–21
  3. Whitelaw A, Cherian S, Pople I. Transforming growth factor-β1: a possible signal molecule for posthemorrhagic hydrocephalus?. Pediatr Res. 1999;46:576–580
  4. Whitelaw A, Cherian S, Thoresen M, Pople I. Posthaemorrhagic ventricular dilation: new mechanisms and new treatment. Acta Paediatr Suppl. 2004;444:11–14
  5. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337–4345
  6. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type β rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167–4171
  7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839
  8. Okamoto T, Takahashi S, Nakamura E, Nagaya K, Hayashi T, Shirai M, et al. Matrix metalloproteases in infants with posthemorrhagic hydrocephalus. Early Hum Dev. 2008;84:137–139
  9. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathway in progressive renal interstitial fibrosis. J Am Soc Nephrol. 2003;14:3047–3060
  10. Liu Y, Rajur K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int. 2000;58:2028–2043
  11. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001;59:2023–2038
  12. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, et al. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol. 2004;164:1091–1098
  13. Tada T, Zhan H, Tanaka Y, Hongo K, Matsumoto K, Nakamura T. Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor beta 1. Neurobiol Dis. 2006;21:576–586
  14. Okamoto T, Takahashi S, Nakamura E, Nagaya K, Hayashi T, Fujieda K. Transforming growth factor-β1 induces matrix metalloproteinase-9 expression in human meningeal cells via ERK and Smad pathways. Biochem Biophys Res Commun. 2009;383:475–479
  15. Yushchenko M, Weber F, Mader M, Scholl U, Maliszewska M, Tumani H, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primary related to CSF cell count. J Neuroimmunol. 2000;110:244–251
  16. Sulik A, Wojtkowska M, Oldak E. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of children with echovirus type 30 and mumps meningitis. Scand J Immunol. 2008;68:323–327
  17. Tsuboi Y, Kakimoto K, Akatsu H, Daikuhara Y, Yamada T. Hepatocyte growth factor in cerebrospinal fluid in neurologic disease. Acta Neurol Scand. 2002;106:99–103
  18. Nayeri F, Nilsson I, Hagberg L, Brudin L, Roberg M, Soderstrom C, et al. Hepatocyte growth factor levels in cerebrospinal fluid: a comparison between acute bacterial and nonbacterial meningitis. J Infect Dis. 2000;181:2092–2094
  19. Miyazawa T, Matsumoto K, Ohmichi H, Katoh H, Yamashita T, Nakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Cereb Blood Flow Metab. 1998;18:345–348
  20. Honda S, Kagoshima M, Wanaka A, Tohyama M, Matsumoto K, Nakamura T. Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res. 1995;32:197–210

PII: S0378-3782(10)00081-2

doi: 10.1016/j.earlhumdev.2010.03.007

Early Human Development
Volume 86, Issue 4 , Pages 251-254 , April 2010

Article Tools

* Image Usage & Resolution